๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 6 Beijing 6 Shanghai 6 Hangzhou 4 Xi'an 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou6 Beijing6 Shanghai6 Hangzhou4 Xi'an1
All 10 locations
Target enrolment
to

Trials with a site in Hangzhou

4 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
The Efficacy and Safety of IBI351, Cetuximab ฮฒ Combined With FOLFIRI as First-line /IBI351, Cetuximab ฮฒ as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
NCT06959589Colorectal Cancer Metastatic, KRAS G12C Mutation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
50
Hangzhou
2025-05-22
Recruiting
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
NCT06992648Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
302
Hangzhou
2025-04-01
Recruiting
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
NCT06540326Colorectal Cancer Metastatic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2024-11-12
Recruiting
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
NCT05501353Colorectal Cancer Metastatic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
125
Hangzhou
2022-07-22
Rows per page Showing 1–4 of 4
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4 of those studies with a site in Hangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hangzhou?

3 of the 4 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hangzhou), 4 studies
PhaseStudiesRecruitingShare
Phase 22150%
Observational1125%
Phase 31125%

Most active sponsors

Lead sponsors with the most studies (Hangzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine43
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.